Full Product Name
SPG11 (Spatacsin, Colorectal Carcinoma-associated Protein, Spastic Paraplegia 11 Protein, KIAA1840, FLJ21439, DKFZp762B1512, FLJ21439)
Product Synonym Names
Anti -SPG11 (Spatacsin, Colorectal Carcinoma-associated Protein, Spastic Paraplegia 11 Protein, KIAA1840, FLJ21439, DKFZp762B1512, FLJ21439)
Product Gene Name
anti-SPG11 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence
MLRKILASQQ PDRCKRAQAF ISTQGLKPDT VAELVAEEVT RELLTSSQGT GHKQMFNPTE ESQTFLQLTT LCQDRTLVGM KLLDKISSVP HGELSCTTEL LILAHHCFTL TCHMEGIIRV LQAAHMLTDN HLAPSEEYGL VVRLLTGIGR YNEMTYIFDL LHKKHYFEVL MRKKLDPSGT LKTALLDYIK RCRPGDSEKH NMIALCFSMC REIGENHEAA ARIQLKLIES QPWEDSLKDG HQLKQLLLKA LTLMLDAAES YAKDSCVRQA QHCQRLTKLI TLQIHFLNTG QNTMLINLGR HKLMDCILAL PRFYQASIVA EAYDFVPDWA EILYQQVILK GDFNYLEEFK QQRLLKSSIF EEISKKYKQH QPTDMVMENL KKLLTYCEDV YLYYKLAYEH KFYEIVNVLL KDPQTGCCLK DMLAG
Chromosome Location
Chromosome: 15; NC_000015.9 (44854894..44955876, complement). Location: 15q14
3D Structure
ModBase 3D Structure for Q96JI7
Specificity
Recognizes human FLJ21439.
Purity/Purification
Affinity Purified
Purified by Protein A affinity chromatography.
Form/Format
Supplied as a liquid in PBS, pH 7.2.
Immunogen
Full length human FLJ21439, aa1-425 (AAH24161.1).
Preparation and Storage
May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Other Notes
Small volumes of anti-SPG11 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-SPG11 antibody
Interacts with AP5Z1, AP5B1, AP5S1 and ZFYVE26.
Product Categories/Family for anti-SPG11 antibody
Antibodies; Abs to Cancer Markers
Applications Tested/Suitable for anti-SPG11 antibody
Western Blot (WB)
Application Notes for anti-SPG11 antibody
Suitable for use in Western Blot.
NCBI/Uniprot data below describe general gene information for SPG11. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001153699.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001160227.1
[Other Products]
UniProt Primary Accession #
Q96JI7
[Other Products]
UniProt Secondary Accession #
Q4VC11; Q58G86; Q69YG6; Q6NW01; Q8N270; Q8TBU9; Q9H734; A8KAX9; B9EK60; F5H3N6[Other Products]
UniProt Related Accession #
Q96JI7[Other Products]
Molecular Weight
278,868 Da[Similar Products]
NCBI Official Full Name
spatacsin isoform 2
NCBI Official Synonym Full Names
spastic paraplegia 11 (autosomal recessive)
NCBI Official Symbol
SPG11??[Similar Products]
NCBI Official Synonym Symbols
KIAA1840
??[Similar Products]
NCBI Protein Information
spatacsin; spastic paraplegia 11 protein; colorectal carcinoma-associated protein
UniProt Protein Name
Spatacsin
UniProt Synonym Protein Names
Colorectal carcinoma-associated protein; Spastic paraplegia 11 protein
UniProt Gene Name
SPG11??[Similar Products]
UniProt Synonym Gene Names
KIAA1840??[Similar Products]
UniProt Entry Name
SPTCS_HUMAN
NCBI Summary for SPG11
The protein encoded by this gene is a potential transmembrane protein that is phosphorylated upon DNA damage. Defects in this gene are a cause of spastic paraplegia type 11 (SPG11). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]
UniProt Comments for SPG11
Subunit structure: Interacts with AP5Z1, AP5B1, AP5S1 and ZFYVE26. Ref.10
Subcellular location: Membrane; Multi-pass membrane protein
Potential. Cytoplasm ? cytosol. Nucleus. Note: Mainly cytoplasmic. Ref.8
Tissue specificity: Expressed in all structures of brain, with a high expression in cerebellum. Ref.8
Involvement in disease: Spastic paraplegia 11, autosomal recessive (SPG11) [MIM:604360]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.8 Ref.11
Sequence caution: The sequence AAH24161.2 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.The sequence AAX54692.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.The sequence BAB15065.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.The sequence BAC03600.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.
Research Articles on SPG11
1. This study widens the spectrum of mutations in SPG11
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
